Cargando…
Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2
Erb-b2 receptor tyrosine kinase 2 (ErbB2) is an oncogene that frequently overexpressed in a subset of cancers. Anti-ErbB2 therapies have been developed to treat these types of cancers. However, less is known about how anti-ErbB2 drugs affect the trafficking and degradation of ErbB2. We demonstrate t...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941056/ https://www.ncbi.nlm.nih.gov/pubmed/36824069 http://dx.doi.org/10.1016/j.bbrep.2023.101436 |